Insulin receptor (basal)

Assets acting on this target.

Class
Basal insulin analog

The insulin receptor is a cell-surface receptor tyrosine kinase found on liver, muscle, and fat cells. When insulin binds, the receptor autophosphorylates and activates intracellular signaling that promotes glucose uptake into cells, suppresses glucose production by the liver, and regulates fat and protein metabolism. In diabetes, the body either fails to produce sufficient insulin or cannot respond to it effectively, leading to chronically elevated blood glucose. Basal insulin analogs are engineered forms of insulin designed to provide a steady, low-level activation of the insulin receptor over an extended period, mimicking the continuous background insulin secretion that occurs between meals and overnight in people without diabetes. This is distinct from rapid-acting insulins, which are designed to handle the glucose surge after meals. Achieving a flat, prolonged action profile reduces peaks and troughs in insulin exposure, which helps maintain stable blood glucose control while minimizing episodes of hypoglycemia (dangerously low blood sugar) that can occur when insulin activity spikes unpredictably. This mechanism is central to management of both type 1 diabetes, where the pancreas produces little or no insulin, and advanced type 2 diabetes, where endogenous insulin production becomes insufficient despite ongoing insulin resistance.

By indication

Related mechanisms

Insulin receptor (basal) drugs compared

13 drugs, stage by indication
13 drugs acting on Insulin receptor (basal): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
insulin degludecTresibaNovo NordiskpeptideApprovedApproved in Type 1 Diabetes; Approved in Type 2 Diabetes
insulin detemirLevemirNovo NordiskpeptideApprovedApproved in Type 1 Diabetes; Approved in Type 2 Diabetes
Insulin Efsitora AlfaOnswikEli Lillyprotein (Fc-fusion)ApprovedApproved in Type 2 Diabetes
insulin glargineLantusSanofipeptideApprovedApproved in Type 1 Diabetes; Approved in Type 2 Diabetes
Insulin glargine (Basaglar)BasaglarBoehringer Ingelheim, Eli LillypeptideApprovedApproved in Type 1 Diabetes; Approved in Type 2 Diabetes
Insulin glargine (Toujeo)ToujeoSanofipeptideApprovedApproved in Type 1 Diabetes; Approved in Type 2 Diabetes
insulin icodecAwiqliNovo NordiskpeptideApprovedApproved in Type 2 Diabetes
GZR33Gan & Lee PharmaceuticalspeptidePhase 3Phase 3 in Type 2 Diabetes
IcoSemaKyinsuNovo NordiskpeptidePhase 3Phase 3 in Type 2 Diabetes
Insulin sudelidec (INS068)Jiangsu Hengrui PharmaceuticalspeptidePhase 3Phase 3 in Type 2 Diabetes
SHR-3167Jiangsu Hengrui PharmaceuticalspeptidePhase 3Phase 3 in Type 2 Diabetes
GZR101Gan & Lee PharmaceuticalspeptidePhase 2Phase 2 in Type 2 Diabetes
UBT38006United Bio-Technology (Hengqin)peptidePhase 1Phase 1 in Type 2 Diabetes

← all mechanisms